1. Evaluating Antibody-Dependent Cell-Mediated Cytotoxicity by Chromium Release Assay.
- Author
-
van der Haar Àvila I, Marmol P, Kiessling R, and Pico de Coaña Y
- Subjects
- Antibody-Dependent Cell Cytotoxicity drug effects, Antibody-Dependent Cell Cytotoxicity immunology, Breast Neoplasms blood, Breast Neoplasms immunology, Breast Neoplasms pathology, Cell Line, Tumor, Cell Separation instrumentation, Cell Separation methods, Cytotoxicity Tests, Immunologic instrumentation, Female, Flow Cytometry instrumentation, Flow Cytometry methods, GPI-Linked Proteins immunology, GPI-Linked Proteins metabolism, Humans, Killer Cells, Natural metabolism, Receptor, ErbB-2 antagonists & inhibitors, Receptor, ErbB-2 metabolism, Receptors, IgG immunology, Receptors, IgG metabolism, Trastuzumab pharmacology, Chromium Radioisotopes metabolism, Cytotoxicity Tests, Immunologic methods, Killer Cells, Natural immunology
- Abstract
Antibody-dependent cell-mediated cytotoxicity (ADCC) is a mechanism in which immune cell activation is induced by the cross-linking of CD16 with the Fc region of antibodies that at the same time bind specifically to cell surface antigens. ADCC stimulates the secretion of perforin, granzymes, and cytokines leading to lysis of the malignant cells. Natural killer (NK) cells express the CD16 receptor and can therefore be activated by ADCC to kill tumor cells. To study the cytotoxicity of NK cells against cancer cells, an ADCC-based assay is described: the chromium release assay. In this method, the antibody trastuzumab, which binds specifically to HER2-positive malignant cells, is used to trigger ADCC.
- Published
- 2019
- Full Text
- View/download PDF